Physician profile
Kendell Mann
NPI 1053384347
$11,380.17
in general payments reported to CMS, 2019-2025
38 companies · $2,033 in 2025
The $2,033 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,638 · 2020: $1,083 · 2021: $1,808 · 2022: $1,147 · 2023: $1,501 · 2024: $2,171 · 2025: $2,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,704.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,250.17 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,414.53 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,099.80 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $989.93 | 2019-2025 | |
| Janssen Biotech, INC. | $597.51 | 2019-2025 | Tremfya, Stelara, Simponi |
| Qol Medical, LLC | $494.97 | 2019-2025 | Sucraid, Sucraid |
| Pfizer INC. | $451.71 | 2019-2025 | |
| Celgene Corporation | $413.94 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $267.82 | 2019-2024 | Linzess |
| Lilly USA, LLC | $246.36 | 2023-2025 | Omvoh |
| Madrigal Pharmaceuticals | $229.90 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $227.10 | 2019-2025 | Ocaliva |
| Genzyme Corporation | $210.64 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $187.52 | 2023-2025 | Dupixent |
| Celltrion USA INC. | $152.53 | 2024-2025 | Vegzelma |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $151.54 | 2022-2025 | Ibsrela |
| Daiichi Sankyo INC. | $125.11 | 2019-2022 | |
| Intuitive Surgical, INC. | $112.90 | 2019 | |
| Aimmune Therapeutics, INC. | $104.02 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $77.05 | 2024-2025 | Voquezna |
| Laborie Medical Technologies Corp. | $75.54 | 2023 | |
| Nestle Healthcare Nutrition INC. | $52.23 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $50.88 | 2019-2023 | Dificid |
| Endo Pharmaceuticals INC. | $50.41 | 2019-2020 | |
| Allergan, INC. | $49.56 | 2019-2020 | |
| Redhill Biopharma INC. | $43.41 | 2021-2022 | |
| Shionogi INC | $39.45 | 2019 | |
| Echosens North America, INC. | $34.45 | 2024 | Fibroscan |
| Alfasigma USA, INC. | $28.65 | 2020 | |
| Ferring Pharmaceuticals INC. | $26.26 | 2019-2020 | |
| Lucid Diagnostics INC. | $19.16 | 2023 | |
| Capsovision, INC. | $18.64 | 2023 | Capsocam Plus |
| Ucb, INC. | $16.09 | 2019 | |
| Exact Sciences Corporation | $15.23 | 2023 | Cologuard Collection Kit |
| Portola Pharmaceuticals, LLC | $14.69 | 2019 | |
| Novo Nordisk INC | $14.19 | 2025 | Wegovy |
| Sandoz INC. | $13.60 | 2023 | Hyrimoz |
| Oxford Immunotec USA INC | $12.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendell Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.